Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon, Inc.

http://www.cephalon.com

Latest From Cephalon, Inc.

BeiGene-Glenmark Deal Set Tevimbra, Brukinsa On India Trajectory

Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.

Commercial India

Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval

Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.

Business Strategies Clinical Trials

Oncology Reinvents Itself To Retain Position As Biotech Investors’ Darling

Experts from across the biotech ecosystem spoke at a Citeline-sponsored panel at Swiss Biotech Day to discuss how pent-up demand was driving investment in areas outside of oncology, but how there was still room for innovation within the cancer market for those who ask the right questions.

Oncology Strategy

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development
See All

Company Information

  • Other Names / Subsidiaries
    • Arana Therapeutics (Peptech and EvoGenix)
    • BioAssets Development Corporation
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • Zeneus Pharma
    • Mepha
UsernamePublicRestriction

Register